Eflornithine News and Research

RSS

New review aims to help clinicians diagnose and manage PCOS

A recent review article in CMAJ explores the state of current knowledge on the diagnosis and treatment of this chronic disorder.

30 Jan 2024

Trial shows acoziborole drug clears body of African sleeping sickness parasites

Researchers evaluate the efficacy and safety of an oral antimicrobial drug acoziborole in patients with human African trypanosomiasis.

4 Dec 2022

Study shows the efficacy of new, single-dose, oral treatment for sleeping sickness

A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new study published in The Lancet Infectious Diseases.

30 Nov 2022

Child with Bachmann-Bupp Syndrome successfully treated in just 16 months

Diagnosing a rare medical condition is difficult. Identifying a treatment for it can take years of trial and error. In a serendipitous intersection of research expertise, an ill patient in this case a child and innovative technology, Bachmann-Bupp Syndrome has gone from a list of symptoms to a successful treatment in just 16 months.

20 Jul 2021

UCI makes tremendous strides in prevention, early detection and treatment of cancer

Like most people, John Gifford wasn't looking forward to a colonoscopy when he arrived on the UCI Medical Center campus in Orange in 2018.

23 Feb 2020

Beat Childhood Cancer consortium's clinical trial offers new hope to children in Canada

Children in Canada who are battling neuroblastoma, a form of cancer, have been granted new hope toward a better prognosis and long-term survival.

8 Aug 2018

Clinical study to find improved treatment for visceral leishmaniasis starts in eastern Africa

A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis has begun in eastern Africa, within the new Afri-KA-DIA Consortium with funding from The European & Developing Countries Clinical Trials Partnership.

13 Apr 2018

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.

9 Sep 2015

DNDi unveils plans to better respond to the needs of neglected patients

After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi's portfolio.

9 Sep 2015

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists are trying to deliver a stern wake-up call to the parasite that causes sleeping sickness.

24 Feb 2015

DNDi awarded USAID grant to develop new treatments for river blindness, elephantiasis

The Drugs for Neglected Diseases initiative has been awarded US$ 10 million by the United States Agency for International Development to develop new treatments for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) - the first-ever USAID grant for neglected tropical disease research and development (R&D).

17 Dec 2014

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to treat river blindness (or onchocerciasis). The world's second leading infectious cause of blindness, river blindness is a neglected tropical disease caused by a filarial worm.

10 Dec 2014

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).

24 Sep 2014

DFID awards 5-year grant to DNDi to advance research and development for neglected diseases

The UK Department for International Development (DFID) has announced its renewed support to the Drugs for Neglected Diseases initiative (DNDi), allocating a total of - 30 million (- 35 million) over the coming five years (2013-2018) to DNDi's Research & Development (R&D) portfolio to fight neglected diseases.

22 Aug 2013

WHO includes new paediatric therapeutic options to EMLc

This week the World Health Organization released its newly updated 4th WHO Model List of Essential Medicines for Children, in which three treatments developed by the Drugs for Neglected Diseases initiative and its partners have now been included.

12 Jul 2013

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

The World Health Organization's new HIV treatment guidelines, released today at the 2013 International AIDS Society Conference, include new antiretroviral therapy recommendations for HIV-infected children, and will mean that more children will be on better treatments.

1 Jul 2013

Sustained engagement, partnership needed to implement new treatments for neglected diseases

Days after two landmark resolutions were adopted at the World Health Assembly - on neglected tropical diseases and on research and development, financing and coordination for the health needs of developing countries - over 400 scientists, representatives and ministers of health, ambassadors, national control programme representatives, African regulators, health workers, public health experts, and activists from 21 African countries and 10 others from around the world gather in Nairobi to take stock of health innovation for neglected diseases in Africa over the past decade.

6 Jun 2013

New Japan-driven initiative to accelerate research, development innovation for neglected diseases

The Drugs for Neglected Diseases initiative, based in Geneva, Switzerland, and DNDi Japan, based in Tokyo, welcome the launch of the Global Health Innovative Technology Fund, an initiative supported by the Japanese government, several Japanese pharmaceutical companies, and the Bill & Melinda Gates Foundation.

9 Apr 2013

DNDi receives 2013 BBVA Foundation Frontiers of Knowledge and Culture Award

Today in Madrid, Spain, the Drugs for Neglected Diseases initiative (DNDi) received the BBVA Foundation 'Frontiers of Knowledge and Culture Award for Development Cooperation'. This EUR 400,000 award will be presented at a ceremony in Madrid, Spain, in June of this year.

27 Feb 2013

DNDi in Latin America wins Carlos Slim Health Award for innovations in drug development

Today the Drugs for Neglected Diseases initiative (DNDi) in Latin America received the Carlos Slim Health Award for 10 years of exceptional work and achievements in research and development (R&D) to deliver new treatments for neglected patients in the region. The $100,000 award will be presented at a ceremony in April in Mexico City.

16 Feb 2013